Physician profile
Charde Phillips
NPI 1588141386
$5,647.10
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,344 · 2022: $2,060 · 2023: $1,217 · 2024: $26.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.73 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $498.15 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $483.14 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Validus Pharmaceuticals LLC | $448.89 | 2021 | |
| Novo Nordisk INC | $319.20 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $283.49 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Idorsia Pharmaceuticals US INC | $256.20 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.53 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $242.48 | 2022 | |
| Pfizer INC. | $197.00 | 2022-2023 | |
| Amgen INC. | $176.14 | 2021-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $159.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.97 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $124.73 | 2021-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $122.40 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charde Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.